Clinical trials: Generalized Anxiety Disorder
- Condition Generalized Anxiety Disorder
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Generalized Anxiety Disorder
Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of 2.5 mg and 10 mg vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
- Trial name
- NCT00731120
- Testing
- Vortioxetine
- Where
- 40 sites in United States
- Volunteers
- 457 people
- Sponsor
- Takeda
Anxiety
Clinical and Cost Effectiveness of Alpha-Stim AID CES
This is a single-centre research study in patients seen within an NHS Improving Access to Psychological Interventions (IAPT) service with suspected generalised anxiety disorder (GAD).
- Trial name
- NCT02901080
- Testing
- Alpha Stim AID cranial electrotherapy stimulation, Pregnancy test, Anxiety questionnaire
- Where
- United Kingdom
- Volunteers
- 161 people
- Sponsor
- Electromedical Products International, Inc.
Generalized Anxiety Disorder
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
GAD subjects maintained on a stable dose of alprazolam for at least four weeks who meet eligibility criteria will be randomized to receive pregabalin vs matching placebo while simultaneously tapering off of alprazolam over 6…
- Trial name
- GAD (NCT00368745)
- Testing
- Pregabalin
- Where
- 21 sites in Costa Rica, Czechia and 5 more
- Volunteers
- 108 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Generalized Anxiety Disorder (GAD), Anxiety, Separation
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Trial name
- NCT01470469
- Testing
- SPD503 (extended-release Guanfacine hydrochloride)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Shire
Generalized Anxiety Disorder
Empower Neuromodulation System - Pilot Study for Anxiety Treatment
This study evaluates the effects of peripheral nerve stimulation on anxiety levels in participants with Generalized Anxiety Disorder (GAD).
- Trial name
- NCT04901481
- Testing
- Empower Neuromodulation System
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Theranova, L.L.C.
Generalized Anxiety Disorder
POC Study in Partially Responsive Generalized Anxiety Disorder
This study aims to evaluate whether PF-06372865 is safe and effective in the treatment of sub-optimally controlled symptoms of generalized anxiety disorder during two 4-week treatment periods using a Sequential Parallel…
- Trial name
- NCT02310568
- Testing
- PF-06372865.
- Where
- 47 sites in United States
- Volunteers
- 90 people
- Sponsor
- Pfizer
Generalized Anxiety Disorder, Panic Disorder
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
An 8-week, open-label trial in 848 subjects at 212 sites to compare time to response in symptoms of anxiety in subjects treated with Niravam™ and a newly prescribed Selective Serotonin Reuptake Inhibitor (SSRI)or Serotonin and…
- Trial name
- NCT00266409
- Testing
- Niravam, SSRI/SNRI
- Where
- United States
- Volunteers
- 418 people
- Sponsor
- UCB Pharma
Anxiety Disorders
AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
- Trial name
- NCT00808249
- Testing
- AZD7325
- Where
- 52 sites in United States
- Volunteers
- 725 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
- Trial name
- NCT00730691
- Testing
- Vortioxetine, Duloxetine
- Where
- 66 sites in United States
- Volunteers
- 781 people
- Sponsor
- Takeda
Generalized Anxiety Disorder
Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)
A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.
- Trial name
- NCT00595231
- Testing
- SYN111
- Where
- 2 sites in United States
- Volunteers
- 239 people
- Sponsor
- Biotie Therapies Inc.
Generalized Anxiety Disorder
Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder
The purpose of this study is to characterize the safety and efficacy in patients with generalized anxiety disorder after short- (3 months) and long-term (6 months) use of Pregabalin (Lyrica).
- Trial name
- NCT00624780
- Testing
- Pregabalin, Lorazepam
- Where
- 57 sites in Argentina, Austria and 14 more
- Volunteers
- 615 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Generalized Anxiety Disorder
Duloxetine for the Treatment of Generalized Anxiety Disorder
This is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder
- Trial name
- NCT00803361
- Testing
- Duloxetine
- Where
- 7 sites in China
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Generalized Anxiety Disorder (GAD)
EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
To evaluate the efficacy of EDG004 compared to placebo for the treatment of adult patients with GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 5th Ed.
- Trial name
- NCT02305797
- Testing
- Extended-release lorazepam
- Where
- United States
- Volunteers
- 495 people
- Sponsor
- Edgemont Pharmaceuticals, LLC
Anxiety Neuroses, Anxiety States, Neurotic
A Study in Pediatric Participants With Generalized Anxiety Disorder
The purpose of this study is to find out if duloxetine [30-120 milligrams (mg)] given once a day by mouth for 10 weeks to children and adolescents, is better than placebo when treating Generalized Anxiety Disorder (GAD).
- Conditions
- Anxiety Neuroses, Anxiety States, Neurotic, Neuroses, Anxiety
- Trial name
- NCT01226511
- Testing
- Duloxetine
- Where
- 24 sites in United States, Mexico and 1 more
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Treatment Resistant Depression, Generalized Anxiety Disorder
An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay
Genomind has developed and introduced a battery of genetic tests, the Genecept Assay, which clinicians can administer to patients using a simple saliva sample technique. The present study proposes to enroll 1.
- Trial name
- COM-1 (NCT01507155)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Genomind, LLC
Generalized Anxiety Disorder
Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).
- Trial name
- VLZ-MD-06 (NCT01766401)
- Testing
- Vilazadone
- Where
- 30 sites in United States
- Volunteers
- 402 people
- Sponsor
- Forest Laboratories
Anxiety Disorders
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder.
- Trial name
- NCT00389064
- Testing
- Quetiapine XR
- Where
- 43 sites in United States, Estonia and 3 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
To determine the safety and efficacy of SEP-225441 (eszopiclone) in subjects with generalized anxiety disorder (GAD).
- Trial name
- NCT00616655
- Testing
- eszopiclone
- Where
- 57 sites in United States
- Volunteers
- 456 people
- Sponsor
- Sumitomo Pharma America, Inc.
Anxiety Disorders
Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
- Trial name
- NCT00807937
- Testing
- AZD7325, Lorazepam
- Where
- 51 sites in United States
- Volunteers
- 369 people
- Sponsor
- AstraZeneca
Anxiety Disorders,Generalized Anxiety Disorder
A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
This is a study in minors (7 to 17 years old) diagnosed with generalized anxiety disorder (GAD) and evaluated using standard questionnaires as having at least moderate severity of GAD.
- Trial name
- NCT03924323
- Testing
- Escitalopram
- Where
- 39 sites in United States
- Volunteers
- 273 people
- Sponsor
- AbbVie